The risk of Angiotensin Converting Enzyme Inhibitor (ACEI) and Calcium Channel Blocker (CCB) used on Obstructive Sleep Apnea (OSA) incidence in hypertension patients

Abstract

Abstract Background: The administration of angiotensin-converting enzyme inhibitor (ACEI) and calcium channel blocker (CCB) therapy is known to have a side effect of a dry cough that would trigger OSA. Further research is needed to compare the effect of these two drugs on the side effects of OSA, which could trigger high-risk patient conditions. Objective: To determine the risk of using ACE and CCB on the incidence of OSA using a case-control study method at Dau Primary Health Center. Methods: Demographic data were collected on 207 respondents aged 40-60 years by collecting Data Collection Sheets and Berlin questionnaires to determine the risk of OSA in respondents. Then, statistical analysis was carried out by determining the odds ratio (OR). Results: The results showed that one of the factors BMI (obese BMI; OR=1.33; 95% CI=0.11-15.70) induces OSA with the highest OR value compared to other factors. Conclusion: Obese patient has a 1.33 times greater risk of OSA with ACEI and CCB therapy than non-obese. It is necessary to conduct further research with a larger sample size related to OSA’s assessment associated with this therapy to improve patients’ quality of life. Keywords: Obstructive sleep apnea, ACE inhibitors, calcium channel blockers, hypertension